Previous 10 | Next 10 |
InMed announced a non-binding letter of intent to acquire BayMedica Inc. The move is designed to grow InMed’s market presence and strengthen its operations The two companies have had a reciprocal research collaboration that dates back to November 2020 InMed looks to capitaliz...
The past few decades have seen cannabis progress from an intensely policed drug with no perceived medical applications to a “ miracle drug ” with a plethora of health benefits. Anecdotal reports and preliminary studies have found it to be effective against, among other things, ...
InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The ...
VANCOUVER, British Columbia, July 02, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for ...
InMed announced its intent to acquire BayMedica, a revenue stage rare cannabinoid manufacturer. The company will have batches of rare cannabinoids on the market in 2021. It has pre-clinical and clinical stage studies using rare cannabinoids to treat skin and eye symptoms. InMe...
BSQUARE Corporation (BSQR) +77%.Exela Technologies (XELA) +59% after rollout of its Robotic Process Automation platform.Cerevel Therapeutics Holdings (CERE) +40% after positive results from its early-stage trial of CVL-231.Auddia (AUUD) +37% after launching its flagship app.Ver...
InMed Pharmaceuticals (INM) has entered into a non-binding letter of intent ((LOI)) to acquire California based BayMedica that specializes in the manufacture and commercialization of rare cannabinoids. In addition to their manufacturing and commercial activities in the hea...
InMed Pharmaceuticals (INM) inks securities purchase agreement to raise ~$12M through the issuance of 4,036,327 common shares and warrants to purchase equal number of common shares, at $2.973/share and warrant in a private placement priced at-the-market. The five-year warrants have an exercis...
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for ...
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for ...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...